17 completed, 4 recruiting, 3 not yet recruiting, 2 terminated. 13 Phase 2, 7 Phase 1, 3 Not applicable, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 9, Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 7 | Completed 7 |
| Not applicable | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow Recurrent Cervical Cancer: new trials by email Literature Review of Recurrent Cervical Cancer trials Research Report on Recurrent Cervical Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer Reirradiation, Total Ablative Strategy - Recurrent Gynecologic Cancer, Recurrent Uterine Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-06-11 | 2026-10-16 | |
| Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer Biospecimen collection (peripheral blood and paraffin tumor tissue) - Cervical Cancer, Recurrent Cervical Cancer | Not yet recruiting | Zhejiang Cancer Hospital | 60 | 2026-06-01 | 2026-06-29 | |
| A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer SHR-A2102 for Injection, Pemetrexed Disodium for Injection, Gemcitabine Hydrochloride for Injection - Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 398 | 2026-03-30 | 2026-04-06 |
| QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab - Recurrent Cervical Cancer, Metastatic Cervical Cancer | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 25 | 2025-10-15 | 2025-09-22 | |
| The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC RC48, QL1706 - Recurrent Cervical Cancer | Phase 2 | Not yet recruiting | Qilu Hospital of Shandong University | 33 | 2025-10-01 | 2025-09-15 |
| PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer PD-1 antibody, PD-L1 antibody, Chemotherapy and bevacizumab (CT-BEV) - Metastatic Cervical Cancer, Persistent Cervical Cancer | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-05-28 |
| Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy Cervical Cancer, Locally Advanced Cervical Cancer | Recruiting | MSD Italia S.r.l. | 200 | 2024-12-17 | 2025-07-20 | |
| First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer Camrelizumab, Apatinib, Paclitaxel - Stage IVB Cervical Cancer, Recurrent Cervical Cancer | Phase 2 | Terminated | Sun Yat-Sen University Cancer Center | 35 | 2021-07-30 | 2026-07-29 |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer AK104 - Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 2 | Completed | Akeso | 30 | 2020-07-15 | 2025-02-28 |
| Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks - Cervical Cancer, Recurrent Cervical Cancer | Phase 2 | Terminated | University of South Alabama | 5 | 2020-04-16 | 2022-06-07 |
| Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer anti-PD-1+Albumin-Bound Paclitaxel - Recurrent Cervical Cancer | Phase 2 | Completed | Sun Yat-sen University | 27 | 2020-01-13 | 2026-03-10 |
| Genetic Mutation in Recurrent Cervical Cancer Multi-gene panel testing - Recurrent Cervical Cancer, Nucleotide Variant | Unknown | Lei Li | 300 | 2019-12-19 | 2019-12-20 | |
| Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer Cryosurgery, NK immunotherapy - Recurrent Cervical Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers educational intervention, telephone-based intervention, quality-of-life assessment - Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter | Not applicable | Completed | City of Hope Medical Center | 200 | 2013-10-29 | 2026-10-01 |
| Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer eribulin mesylate - Recurrent Cervical Cancer, Stage IIIA Cervical Cancer | Phase 2 | Completed | University of Southern California | 32 | 2012-08-09 | 2025-11-06 |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride - Leydig Cell Tumor, Ovarian Sarcoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 12 | 2012-05-01 | 2015-08-04 |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer questionnaire administration, quality-of-life assessment, psychosocial assessment and care - Anxiety Disorder, Depression | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 39 | 2010-10-01 | 2015-10-09 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer triapine, cisplatin, external beam radiation therapy - Recurrent Cervical Cancer, Recurrent Vaginal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2009-07-01 | 2017-11-17 |
| Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies stereotactic radiosurgery, quality-of-life assessment - Fallopian Tube Cancer, Ovarian Sarcoma | Phase 2 | Completed | Case Comprehensive Cancer Center | 50 | 2009-05-01 | 2013-11-28 |
Showing 20 of 28. Sign in to see all of them.
Uterine Cervical Neoplasms (28) · Carcinoma, Ovarian Epithelial (9) · Vaginal Neoplasms (8) · Vulvar Neoplasms (7) · Endometrial Neoplasms (6) · Breast Neoplasms (5) · Fallopian Tube Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colonic Neoplasms (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Rectal Neoplasms (4) · Anus Neoplasms (3) · Breast Neoplasms, Male (3) · Carcinoma, Hepatocellular (3)
Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Genital Diseases (28) · Genital Diseases, Female (28) · Genital Neoplasms, Female (28) · Neoplasms (28) · Neoplasms by Site (28) · Urogenital Diseases (28) · Urogenital Neoplasms (28) · Uterine Cervical Diseases (28) · Uterine Diseases (28) · Uterine Neoplasms (27) · Adnexal Diseases (10) · Carcinoma (10) · Endocrine Gland Neoplasms (10)
Bevacizumab (3) · Cisplatin (3) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (2) · Carboplatin (2) · Early Intervention, Educational (2) · Erlotinib Hydrochloride (2) · Gemcitabine (2) · Methods (2) · Paclitaxel (2) · Radiosurgery (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 7-hydroxystaurosporine (1) · Behavior Therapy (1) · Brachytherapy (1) · Colposcopy (1)
National Cancer Institute (NCI) (8) · Case Comprehensive Cancer Center (2) · University of Southern California (2) · Affidea Nu-med Center of Oncological DIagnostics and Therapy (1) · Akeso (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · City of Hope Medical Center (1) · Fuda Cancer Hospital, Guangzhou (1) · Lei Li (1) · MSD Italia S.r.l. (1) · N.N. Alexandrov National Cancer Centre (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1) · Qilu Hospital of Shandong University (1) · Sun Yat-Sen University Cancer Center (1)
United States (15) · China (6) · Australia (1) · Belarus (1) · Canada (1) · Italy (1) · New Zealand (1) · Poland (1)
Charles Kunos (2) · Agustin Garcia (1) · Amy Halverson (1) · Antonius Miller (1) · Barbara Andersen, PhD (1) · Betty Ferrell (1) · Bradley Monk (1) · Helen Mackay (1) · Jibing Chen, MD, PhD (1) · Lei Li (1) · Leslie Randall, MD (1) · Lynda Roman, MD (1) · Paula Fracasso (1) · Peng Li (1) · Robert DeBernardo, MD (1)
PMID 22105720, PMID 36185311, PMID 38106561
U01CA062502 (2), U10CA027469 (2), P30CA043703 (1), P30CA044579 (1), R21CA135005 (1), U01CA076576 (1), U10CA031946 (1)